A 2014 JAMA study found that fewer than 9% of US patients diagnosed with alcohol use disorder were ever offered any FDA-approved medication for it. Twelve years later, the gap has narrowed but remains stubbornly wide. Naltrexone has been generic since 2013. It costs almost nothing. The evidence base goes back to 1994. Yet most people who would benefit from it never hear about it from their doctor. This article is part of our Naltrexone hub, the complete guide to using naltrexone for alcohol use disorder.
This article is about why that gap exists, what’s true and what’s myth in the standard objections, and how to walk into a doctor’s appointment prepared to advocate for the medication you want. If you’ve already been refused once, this article is also about how to push back.
# The scale of the gap
A few numbers to ground the discussion:
- Around 30 million US adults meet criteria for alcohol use disorder in any given year (2023 NSDUH data)
- An estimated 75-85% of them never receive any specialist treatment
- Of those who do receive any treatment, fewer than 10% are prescribed FDA-approved medication
- This means the percentage of people with alcohol use disorder who end up on appropriate medication is roughly 1-2% of the eligible population
The gap is wider than for almost any other treatable chronic condition. Diabetes, hypertension, depression, asthma: all have prescribing rates an order of magnitude higher relative to disease prevalence. Alcohol use disorder is unique in how rarely the available treatment reaches the patient.
The UK and Australia have somewhat better numbers due to NICE guidance and PBS subsidies, but the structural pattern is similar. Specialist alcohol services prescribe; primary care rarely does.
# Why doctors hesitate
Several reasons, ranked roughly by how often they actually drive the decision:
# 1. Insufficient training in addiction medicine
The biggest factor. Most general practitioners receive minimal addiction medicine training during medical school and residency, often less than 10 hours total across years of training. The result: many GPs feel out of their depth managing alcohol use disorder pharmacologically. They refer to specialists who they think will handle it, but specialist wait times can be 3-6 months, and many patients drop out of the referral pathway before they’re seen.
This is a workforce problem, not a stubbornness problem. GPs aren’t refusing naltrexone because they think it’s bad; they’re hesitant because they haven’t prescribed it recently and don’t feel confident answering follow-up questions.
# 2. The persistent abstinence-only mental model
For decades, addiction treatment in the English-speaking world has been dominated by abstinence-only frameworks (12-step recovery, AA, the Minnesota model). These frameworks have helped many people, but they shape clinical thinking in ways that work against medication.
The implicit reasoning often runs: “If the goal is abstinence, then the patient needs to stop drinking, then stay stopped via psychological work. Medication doesn’t really help with either of those.” This thinking misses the entire population of patients who could benefit from reducing their drinking via naltrexone (where abstinence isn’t necessarily the goal), and undersells naltrexone’s role in supporting abstinence in patients who do want to stop.
The framework is changing. Modern guidance from NICE, the American Society of Addiction Medicine, and most other major bodies explicitly supports medication-assisted treatment for alcohol use disorder. But the cultural shift among prescribing clinicians lags behind the guidance.
# 3. Misunderstanding of who qualifies
A common belief: naltrexone is for severe alcohol dependence, the daily-drinker-with-shaking-hands archetype. This is wrong. Modern guidance supports naltrexone across the full spectrum of alcohol use disorder, including mild AUD (2-3 DSM-5 criteria) and moderate AUD (4-5 criteria). Some prescribers will still treat anyone with problematic drinking who wants to address it, regardless of formal diagnosis.
If you’re being told “you don’t seem dependent enough,” this is the answer. The threshold for medication is much lower than many doctors believe.
# 4. Liver function concerns, often overstated
Naltrexone has a black-box warning about hepatotoxicity, but the warning was based on studies using doses much higher than 50mg (up to 300mg). At standard doses, naltrexone causes only modest, reversible LFT elevations in a small minority of patients. The medication is not contraindicated in mild-to-moderate liver disease; only severe liver dysfunction (acute hepatitis, decompensated cirrhosis) is a true contraindication.
A doctor who points to “your liver enzymes” as a reason to refuse naltrexone may be either citing real concerning numbers, or applying the black-box warning more broadly than the evidence supports. Worth asking specifically what their threshold is and whether it matches current guidance.
# 5. Confusion with naloxone
Naloxone (Narcan) is the opioid overdose reversal drug. Naltrexone (Revia, Vivitrol) is the long-acting opioid antagonist for alcohol or opioid use disorder. They sound similar and act on the same receptors, but they’re used for completely different things. Some patients have had GP appointments where the doctor confused the two, then declined to prescribe what they thought was an emergency injection.
If you sense confusion in the conversation, gently clarify: “I’m asking about naltrexone, the daily tablet, not naloxone, which is the overdose reversal.”
# 6. Scheduling and follow-up logistics
Naltrexone benefits from regular follow-up: liver function tests at start and 3-6 months, conversation about side effects in the first month, dose verification on TSM. Many primary care practices are not set up for this kind of structured follow-up on a generic medication that doesn’t generate revenue. The path of least resistance for the practice is to refer out.
This is a real systemic problem, not the patient’s fault. But knowing it explains why some clinicians prefer to send you elsewhere.
# How to walk into the appointment prepared
The single most useful thing you can do: be specific. Don’t say “I want help with my drinking.” Say “I’d like to try naltrexone, either daily 50mg or via the Sinclair Method targeted dosing protocol.” Specificity does three things:
- It signals that you’ve done your homework, which makes the doctor more confident in prescribing
- It gets past the standard “have you considered AA?” deflection
- It makes a specific clinical decision rather than a general “what should we try?” conversation
Bring with you, ideally:
- A self-assessment score: AUDIT-C or AUDIT (we cover this in AlcoScore vs AUDIT-C)
- Recent liver function test results, if you have any
- A drinking diary or app log of your recent drinking pattern (AlcoLog’s CSV export is on Pro for exactly this)
- A specific protocol you want to start with (50mg daily vs Sinclair Method)
Make the request short and clinical:
“I drink 4-5 nights a week, 4-6 drinks per session, and I’d like to reduce. I’ve researched naltrexone and would like to try the Sinclair Method, which is 50mg taken about an hour before drinking. The protocol is well-established for alcohol use disorder and the medication is generic. Are you comfortable prescribing it, or should I see a specialist?”
This framing accomplishes several things at once: signals informed consent, names the protocol, makes the cost question implicit (generic = cheap), and offers an exit ramp (referral) that gives the doctor a face-saving option if they’re not comfortable.
# What to do if refused
The most common refusals and how to respond:
“Have you tried just cutting back / counselling first?” Both can be done alongside naltrexone, not instead of. Cite the Sinclair Method explicitly: the protocol is specifically designed for people continuing to drink while gradually extinguishing the urge. Counselling alone has lower success rates than counselling + medication.
“You don’t seem dependent enough.” Modern guidance supports medication for moderate AUD, not just severe. Ask whether the doctor is following NICE, ASAM, or the relevant national guidance.
“It’s a powerful medication, let’s not go there yet.” Naltrexone is well-tolerated for most people, has been generic for over a decade, and has decades of safety data. Push back politely: “What specifically concerns you about it? My understanding is that side effects are usually mild and transient.”
“I’m not familiar with this medication.” Fair: ask for a referral to someone who is. Don’t accept “no specialist available” as a closure; the pathway exists even if the wait is long.
If a doctor still refuses after a calm, informed conversation, your options:
- Ask for the refusal to be documented in your notes and request a second opinion
- Switch to a different practice or doctor
- Use telemedicine (US) or a private route (UK, AU). See How to Get a Naltrexone Prescription for country-specific routes.
You shouldn’t have to fight for a 30-year-old generic medication with strong evidence. But if you do, persistence usually pays off.
# What’s changing
The treatment gap is closing slowly. Several forces are pushing in the right direction:
- Telemedicine services (Ria Health, Oar Health, Workit Health in the US) prescribe naltrexone routinely without the GP-knowledge bottleneck
- NICE guidance updates and equivalents in other markets explicitly recommend medication for AUD across severity levels
- Patient advocacy and online communities (TSM-focused forums, recovery communities) are spreading awareness faster than clinical training catches up
- Sober-curious cultural shift is moving alcohol questions from shame to mainstream conversation, which makes patients more likely to ask about medication
The trajectory is positive but slow. For now, advocating for yourself remains the most reliable path to treatment.
# How AlcoLog supports the appointment
AlcoLog’s session log gives you the data your prescriber will want to see: drinks per session, sessions per week, total drinks per month, and pattern over time. The history view’s monthly card layout makes for a clean conversation starter at appointments. CSV export of your last 10 sessions is free; unlimited export and PDF reports are on Pro for printing or emailing to your doctor.
The Medications card supports naltrexone alongside acamprosate, disulfiram, gabapentin, topiramate, nalmefene, and recovery supplements. Each medication has its own colour, dose log via the 24-hour time picker, last-24h dose list, and redose timer set in hours and minutes.
AlcoScore deliberately excludes medication use from its scoring. The app’s view: medication is a tool you choose to use, not a behaviour the app should grade you on. Your dose log informs you, not your score. Data stays on your device.
